American Century Companies Inc Apellis Pharmaceuticals, Inc. Transaction History

American Century Companies Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $17.4 Million - $21.1 Million	-226,628 Reduced 98.0%	4,626 $421,000
Q1 2023 May 11, 2023	BUY	$46.59 - $66.96 $20,033 - $28,792	430 Added 0.19%	231,254 $15.3 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $9.32 Million - $13.2 Million	215,553 Added 1411.52%	230,824 $11.9 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $66,916 - $104,141	-1,495 Reduced 8.92%	15,271 $1.04 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $6,593 - $11,131	188 Added 1.13%	16,766 $758,000
Q1 2022 May 11, 2022	BUY	$35.46 - $54.12 $587,855 - $897,201	16,578 New	16,578 $820,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.